Skip to Content

Clindamycin and Benzoyl Peroxide

Medically reviewed by Drugs.com. Last updated on Oct 10, 2020.

Pronunciation

(klin da MYE sin & BEN zoe il peer OKS ide)

Index Terms

  • Benzoyl Peroxide and Clindamycin
  • Clindamycin Phos/Benzoyl Perox
  • Clindamycin Phosphate and Benzoyl Peroxide

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Gel, External:

Acanya: Clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (50 g) [contains propylene glycol]

BenzaClin: Clindamycin phosphate 1% and benzoyl peroxide 5% (25 g)

BenzaClin with Pump: Clindamycin phosphate 1% and benzoyl peroxide 5% (35 g, 50 g)

Duac: Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g [DSC]) [contains edetate disodium, methylparaben]

Neuac: Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g) [contains methylparaben, propylparaben]

Onexton: Clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (3.5 g, 50 g) [contains propylene glycol]

Generic: Clindamycin phosphate 1% and benzoyl peroxide 5% (25 g, 35 g, 50 g); Clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (50 g); Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g)

Kit, External:

Neuac: Clindamycin phosphate 1.2% and benzoyl peroxide 5% [contains cetyl alcohol, edetate disodium, methylparaben, propylparaben]

Brand Names: U.S.

  • Acanya
  • BenzaClin
  • BenzaClin with Pump
  • Duac [DSC]
  • Neuac
  • Onexton

Pharmacologic Category

  • Acne Products
  • Topical Skin Product
  • Topical Skin Product, Acne

Pharmacology

Benzoyl peroxide: Releases free-radical oxygen, which oxidizes bacterial proteins in the sebaceous follicles, decreasing the number of anaerobic bacteria and decreasing irritating-type free fatty acids.

Clindamycin: Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism.

Use: Labeled Indications

Acne: Topical treatment of acne vulgaris

Off Label Uses

Rosacea

Data from a small vehicle-controlled trial suggest that topical clindamycin in combination with benzoyl peroxide may be beneficial for the treatment of moderate to severe inflammatory rosacea [Breneman 2004], [Leyden 2004].

Contraindications

Hypersensitivity to benzoyl peroxide, clindamycin, lincomycin, or any component of the formulation; history of regional enteritis, ulcerative colitis, pseudomembranous colitis or antibiotic-associated colitis

Dosing: Adult

Acne: Topical:

Clindamycin 1.2%/benzoyl peroxide 2.5%: Apply pea-sized amount to affected area once daily; use >12 weeks has not been studied.

Clindamycin 1.2%/benzoyl peroxide 3.75%: Apply pea-sized amount to affected area once daily; use >12 weeks has not been studied.

Clindamycin 1%/benzoyl peroxide 5%: Apply to affected area twice daily (morning and evening).

Inflammatory acne: Topical: Clindamycin 1.2%/benzoyl peroxide 5%: Apply to affected area once daily in the evening.

Rosacea (off-label use): Topical: Clindamycin 1%/benzoyl peroxide 5%: Apply to affected area once daily for 12 weeks (Leyden 2004)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Acne vulgaris: Topical: Children ≥7 years and Adolescents: Limited data available in ages <12 years (Eichenfeld 2013):

Clindamycin 1.2%/benzoyl peroxide 2.5%: Apply pea-sized amount to affected area once daily; use >12 weeks has not been studied

Clindamycin 1.2%/benzoyl peroxide 3.75%: Apply pea-sized amount to affected area once daily; use >12 weeks has not been studied

Clindamycin 1%/benzoyl peroxide 5%: Apply to affected area twice daily (morning and evening)

Inflammatory acne: Topical: Children ≥12 years and Adolescents: Clindamycin 1.2%/Benzoyl peroxide 5%: Apply to affected area once daily in the evening

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Reconstitution

BenzaClin: Prior to dispensing, tap the vial until powder flows freely. Reconstitute clindamycin with purified water; shake well. Add clindamycin solution to benzoyl peroxide gel and stir until homogenous (60 to 90 seconds).

Administration

Skin should be clean and dry before applying. For external use only; avoid applying to inside nose, mouth, eyes, vagina, mucous membranes, and on areas of broken skin.

Storage

Acanya: Prior to dispensing, store in refrigerator, between 2°C to 8°C (36°F to 46°F); do not freeze. Once dispensed, store at room temperature of ≤25°C (≤77°F), protect from freezing, and use within 10 weeks.

BenzaClin: Store unreconstituted product at room temperature of ≤25°C (≤77°F); do not freeze. Once reconstituted and dispensed, store at room temperature of ≤25°C (≤77°F) and use within 3 months.

Duac: Prior to dispensing, store in refrigerator, between 2°C to 8°C (36°F to 46°F); do not freeze. Once dispensed, store at room temperature of ≤25°C (≤77°F), protect from freezing, and use within 60 days.

Onexton: Prior to dispensing, store in a refrigerator at 2°C to 8°C (36°F to 46°F). Once dispensed, store at or below 25°C (77°F). Protect from freezing.

Drug Interactions

Dapsone (Topical): Benzoyl Peroxide may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the use of these agents in combination may cause skin and facial hair to temporarily turn a tan or yellow/orange color. Monitor therapy

Erythromycin (Systemic): May diminish the therapeutic effect of Clindamycin (Topical). Avoid combination

Erythromycin (Topical): May diminish the therapeutic effect of Clindamycin (Topical). Avoid combination

Isotretinoin (Topical): Benzoyl Peroxide may diminish the therapeutic effect of Isotretinoin (Topical). Management: Avoid combined use of benzoyl peroxide and topical isotretinoin. If concomitant use cannot be avoided, consider separating application times and monitoring for signs and symptoms of clinical failure of isotretinoin. Consider therapy modification

Neuromuscular-Blocking Agents: Clindamycin (Topical) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Monitor therapy

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.

>10%:

Dermatologic: Application site scaling (≤21%), local dryness (≤16%)

Local: Application site erythema (<31%), local desquamation (2% to 19%), application site itching (≤17%)

1% to 10%:

Dermatologic: Stinging of the skin (application site: ≤7%), sunburn (local; 1%)

Local: Application site burning (≤10%), application site reaction (3%)

<1%, postmarketing, and/or case reports: Anaphylaxis, application site irritation, application site pain, contact dermatitis, hypersensitivity reaction, local discoloration, local skin exfoliation, skin rash, urticaria

Warnings/Precautions

Concerns related to adverse effects:

• Bleaching effects: Benzoyl peroxide may bleach hair, colored fabric, or carpeting.

• Diarrhea: Systemic absorption may occur after topical use of clindamycin. C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis have been reported and have been observed >2 months postantibiotic treatment. Use of parenteral and systemic clindamycin has resulted in severe colitis (including fatalities). Discontinue drug if significant diarrhea, abdominal cramps, or passage of blood and mucus occurs.

• Hypersensitivity: Anaphylaxis and allergic reactions have been reported, may occur within minutes to a day or longer, and differ from local skin irritation.

• Skin irritation: Use concomitant topical acne therapy with caution; cumulative irritancy may occur, especially with the use of peeling, desquamating, or abrasive agents.

Concurrent drug therapy issues:

• Sulfone products: Concomitant use of benzoyl peroxide with sulfone products (eg, dapsone, sulfacetamide) may cause temporary discoloration (yellow/orange) of facial hair and skin. Application of products at separate times during the day or washing off benzoyl peroxide prior to application of other products may avoid skin discoloration (Dubina 2009).

Other warnings/precautions:

• Appropriate use: For external use only; not for vaginal or ophthalmic use. Avoid contact with mucous membranes. Inform patients to use skin protection and minimize prolonged exposure to sun and avoid tanning beds or sun lamps.

Pregnancy Considerations

Topical therapy is preferred for the treatment of acne during pregnancy. The combination of topical clindamycin with benzoyl peroxide is recommended for mild to moderate inflammatory acne in pregnant women (Chien 2016).

Refer to individual monographs for additional information.

Patient Education

What is this drug used for?

• It is used to treat pimples (acne).

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Dry skin

• Itching

• Burning

• Skin irritation

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Bowel problems like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.